Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19

Temistocles Diaz, Barry H. Trachtenberg, Samuel J. K. Abraham, Rao KosagiSharaf, Armando A. Durant-Archibold

Open source

DOI
10.3389/fcvm.2020.562708
Published
2020-11-30
Container
Frontiers in Cardiovascular Medicine
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fcvm.2020.562708,
  title = {Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19},
  author = {Temistocles Diaz and Barry H. Trachtenberg and Samuel J. K. Abraham and Rao KosagiSharaf and Armando A. Durant-Archibold},
  year = {2020},
  journal = {Frontiers in Cardiovascular Medicine},
  doi = {10.3389/fcvm.2020.562708},
  url = {https://doi.org/10.3389/fcvm.2020.562708}
}

RIS

TY  - JOUR
TI  - Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
AU  - Temistocles Diaz
AU  - Barry H. Trachtenberg
AU  - Samuel J. K. Abraham
AU  - Rao KosagiSharaf
AU  - Armando A. Durant-Archibold
PY  - 2020
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2020.562708
UR  - https://doi.org/10.3389/fcvm.2020.562708
ER  - 

APA

Diaz, T., Trachtenberg, B. H., Abraham, S. J. K., KosagiSharaf, R., & Durant-Archibold, A. A. (2020). Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2020.562708

Source records